Pharma BD Deal Intelligence
Reclaiming full U.S. Vivitrol rights from Cephalon for $16M turned out to be a steal: the returning asset grew from about $4.5M in quarterly sales to $467.9M in 2025 net sales, making it a dominant, durable franchise in injectable addiction treatment.
Not actually an "Alkermes acquires Cephalon" deal — it was Alkermes reclaiming full Vivitrol rights from a failed 2005 co-promotion, and that reclaimed asset became a genuine blockbuster ($467.9M in 2025 sales).
Full analysis, sources & comparables →The Termination Agreement is intended to reduce the Company's cost structure and enhance competitiveness; Cephalon will incur estimated pretax charges of…
Cephalon CEO Frank Baldino stated 'we have a lot of opportunities on our plate and cannot give Vivitrol the focus it deserves' — framing the JV unwind as a…
Carries Alkermes' positive framing of the rights return: 'Overall, we are very pleased to have worked with Cephalon. The collaboration funded key market…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Termination of Vivitrol JV; Alkermes regained full US commercialization rights; $11M from Cephalon (loss share) + $16M Alkermes manufacturing equipment buyback; ~$120M deferred revenue recognized
Not actually an "Alkermes acquires Cephalon" deal — it was Alkermes reclaiming full Vivitrol rights from a failed 2005 co-promotion, and that reclaimed asset became a genuine blockbuster ($467.9M in 2025 sales).
Assessment window: 15yr post-close.
Alcohol use disorder (AUD) is a chronic relapsing brain disease characterized by impaired control over alcohol consumption despite adverse consequences. AUD affects tens of millions of US adults but remains massively undertreated — fewer than 10% of patients ever receive FDA-approved pharmacotherapy. Vivitrol (extended-release naltrexone) was the first once-monthly injectable approved for alcohol dependence (FDA April 2006).
In 2008, the alcohol-dependence pharmacotherapy market was small and fragmented: oral naltrexone (generic ReVia), disulfiram (Antabuse), and acamprosate (Forest's Campral, FDA-approved 2004) competed at low penetration, with adherence widely cited as the binding constraint. Alkermes' Vivitrol was the first once-monthly extended-release naltrexone injectable, approved April 2006 (Drugs.com FDA history). The original June 2005 Alkermes-Cephalon co-commercialization deal made Cephalon the lead marketer; by late 2008, Cephalon CEO Frank Baldino publicly stated 'we have a lot of opportunities on our plate and cannot give Vivitrol the focus it deserves' (per GenEng News and PharmaTimes), reflecting Cephalon's prioritization of Provigil/Treanda. The December 2008 termination returned full US rights to Alkermes for $11M loss-share + $16M equipment buyback, with Alkermes recognizing ~$120M of deferred milestone revenue. Alkermes refocused commercial efforts and obtained the second-indication FDA approval for opioid dependence in October 2010 — repositioning Vivitrol as a dual-indication asset that ultimately exceeded $400M in annual sales by the late 2010s. Source: https://investor.alkermes.com/news-releases/news-release-details/alkermes-regains-full-commercialization-rights-vivitrolr-us/
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Alkermes plc / Cephalon, Inc. (Vivitrol rights) (this deal) | 2008 | $27M | 83 |
| Alkermes plc / Avadel Pharmaceuticals plc | 2025 | $2.1B | — |
| Alkermes plc / Rodin Therapeutics, Inc. | 2019 | $950M | — |
| ViroPharma Incorporated / Lev Pharmaceuticals, Inc. | 2008 | $443M | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Shire plc / Jerini AG | 2008 | $521M | 85 |
| Sanofi-Aventis / Symbion Consumer (Primary Health Care) | 2008 | $544M | 71 |
← Browse all deals · How we score deals
More: 2008 deals · Alkermes plc deals